Dow Up0.25% Nasdaq Up0.65%

Innoviva, Inc. (INVA)

11.15 Down 0.20(1.76%) May 27, 4:00PM EDT
ProfileGet Profile for:
Innoviva, Inc.
951 Gateway Boulevard
South San Francisco, CA 94080
United States - Map
Phone: 650-238-9600

Index Membership:N/A
Industry:Application Software
Full Time Employees:13

Business Summary 

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products includes RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company is also entitled to a 15% interest related to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. Innoviva, Inc. has long-acting muscarinic antagonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Innoviva, Inc.

Corporate Governance 
Innoviva, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 4.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Michael W. Aguiar , 50
Chief Exec. Officer, Pres, Director and Member of Stock Option Committee
Mr. Eric d'Esparbes , 48
Chief Financial Officer and Sr. VP
Dr. Theodore J. Witek Jr., 58
Chief Scientific Officer and Sr. VP
Mr. Michael Eric Faerm , 49
Chief Bus. Officer and Sr. VP
Mr. Jeffrey A. Hagenah Ph.D.,
Chief Patent Counsel and VP
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders